ArticleBMC ophthalmology2025
Safety and efficacy of an extended macular vision intraocular lens (IOL) for age-related macular degeneration (AMD) in real-world settings.
Article in BMC ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo assess the safety and efficacy of the EyeMax Mono (SharpView Ophthalmology) extended macular vision intraocular lens (IOL), in patients with age-related macular degeneration (AMD) undergoing cataract surgery.
methodsThis retrospective multicentre study analyzed real-world data from 196 AMD eyes (146 patients) across 15 medical centres in Europe. All eyes received the single-piece, hydrophobic acrylic, EyeMax Mono IOL. AMD severity was classified by the centre. Outcomes included intraoperative and postoperative complications and changes in corrected distance and near visual acuity (CDVA and CNVA, respectively).
resultsThe postoperative spherical equivalent was + 1.25 ± 1.32 D. Postoperative LogMAR CDVA improved significantly from a baseline of 0.57 ± 0.38 to 0.38 ± 0.34 (n = 191, p < 0.001), while CNVA improved from 0.49 ± 0.32 at baseline to 0.35 ± 0.27 postoperatively (n = 141, p < 0.001). 63% gained > 1 line of CDVA and 27.5% gained ≥ 3 lines. For CNVA, 41.5% gained > 1 line, and 21.8% gained ≥ 3 lines. The greatest gains occurred in intermediate AMD eyes: CDVA + 0.21 logMAR, CNVA + 0.12 logMAR. Only 2.1% of eyes lost > 1 line of CDVA or CNVA.
conclusionsThe EyeMax Mono intraocular lens (IOL) safely enhances both distant (CDVA) and near (CNVA) visual acuity in patients with age-related macular degeneration, particularly in eyes with intermediate AMD. These findings are consistent with those in the published scientific literature.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.